Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Aug 25 2023

Full Issue

Wegovy Shown To Reduce Heart Failure Symptoms For Obese Patients

Separately, researchers are calling for governments to raise the legal smoking age to 22. Also: Charles River Laboratories signed an agreement to help protect horseshoe crabs, whose blue blood is useful for medical testing purposes.

Wegovy, the blockbuster weight-loss medication from Novo Nordisk A/S, alleviated heart failure symptoms in patients with obesity, according to a late-stage trial that adds to the drug’s potential benefits. A weekly dose reduced patients’ ills that can include shortness of breath, fatigue, swelling in the legs and irregular heartbeat, according to findings published Friday in the New England Journal of Medicine. (Muller and Kresge, 8/25)

Young people should be banned from buying tobacco products until they are 22, researchers have suggested after a study found those who start smoking before the age of 20 find it more difficult to quit. Scientists said a rise in the minimum age by governments across the world could reduce nicotine dependence. (Newton, 8/25)

Charles River Laboratories has signed a joint agreement with four entities to enhance protections in South Carolina for horseshoe crabs and a bird that feeds on their eggs, they said on Thursday. The crabs, prized for their milky-blue blood that is used to detect bacterial contamination in intravenous drugs or implants, have been listed as vulnerable by the International Union for Conservation of Nature. (8/24)

In obituaries —

Simon Bensmaia, a trailblazing neuroscientist working on brain computer interfaces allowing amputees and paralyzed patients to control prosthetic and robotic limbs while simultaneously feeling the natural sensations of touch, died Aug. 11 at his home in Chicago. He was 49.The University of Chicago, where Dr. Bensmaia was a professor of organismal biology and anatomy, announced his death but did not cite a cause. (Rosenwald, 8/24)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ